Report Overview

The South Korea pancreatic cancer therapeutics market size stood at around USD xx billion in 2020 and is projected to reach xx billion by 2028, exhibiting a CAGR of around xx% during the forecast period.

Cancer has been the number one cause of death for Koreans for over 36 years, although the survival rate has improved over the years.Pancreatic cancer is the seventh leading cause of cancer death in South Korea. It is a type of malignant cancer that originates from tissues of pancreas. Endocrine and exocrine pancreas cancer are the two forms of pancreatic cancer. Etiological factors include genetic factor, consumption of tobacco smoking, obesity and otheridiopathicreasons. Pancreatic cancer is considered one of the toughest cancers to treat, with extremely poor prognosis. It has a 5-year survival rate of about 10%, and when it progresses to distant metastasis, the survival rate is greatly reduced to about 2%.

 



Market Drivers

According to GLOBOCAN report 7,977 new cases and 7,056 deaths due to pancreatic cancer were reported in South Korea in the year 2020. The 5-year prevalence rate was 12.13 per 100,000. Continuously increasing burden of the disease is a leading factor propelling the market growth. Furthermore, alcohol consumption, smoking, increase in obesity incidence are a few more factors impacting the market drive. Demand of novel drugs for pancreatic cancer treatment, high adoption of immunotherapy, rich pipeline are other factors influencing the market growth. It is understood that market for pancreatic cancer treatment is majorly impeded by high treatment cost and halt of late- stage clinical trials.